Acrivon Therapeutics announced on April 7, 2025, the appointment of Mansoor Raza Mirza, M.D., as its new Chief Medical Officer, effective April 9, 2025. Dr. Mirza is a distinguished oncologist globally recognized for his contributions to the clinical development of novel ovarian and endometrial cancer therapies.
Dr. Mirza will lead all clinical development programs, including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer and the rapidly advancing ACR-2316 Phase 1 study. His extensive experience includes serving as a lead investigator for multiple trials that led to regulatory approvals, such as the PARP inhibitor Zejula for ovarian cancer.
His expertise is expected to be instrumental in guiding ACR-368 towards potential regulatory submission and approval, and in advancing ACR-2316. Dr. Mirza's background as a senior author of national guidelines for endometrial cancer further underscores his qualifications to lead Acrivon's precision oncology pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.